Keyword: Ironwood Pharmaceuticals

The Chinese approval in January opened up a large market with an estimated 14 million irritable bowel syndrome with constipation patients to Linzess.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Allergan and Ironwood debut a new IBS-C awareness campaign that includes a telemedicine link to talk to a doc online.

As it was preparing to divide itself in two last summer, Ironwood pink-slipped 40 staffers. But it turns out those layoffs were only the beginning.

The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move.

Growth for Allergan and Ironwood’s Linzess is easing up, and one analyst thinks Allergan may not be part of the solution.

Zurampic, a drug AstraZeneca once laid out more than $1 billion to get its hands on, has wound up on the scrap heap.

Ironwood may have avoided sparring with activists by introducing an R&D split-off, but its employees paid the price.

Ironwood’s activist investor likes what it’s seen recently from the drugmaker—so much so that it held off on pushing for a spot on the company's board.

Allergan and Ironwood want to help people talk about their guts with their doctors—specifically, their possible IBS symptoms.